Efficacy of Rufinamide as Adjunctive Treatment for Adults With Lennox-Gastaut Syndrome: Subgroup Analysis From a Phase III Trial (P2.056)

Conclusions: Rufinamide demonstrated favourable efficacy, compared with placebo, when used as adjunctive treatment for adults with LGS. Ref: 1Arzimanoglou et al. Lancet.2009;8(1):82-93. Support: Eisai Inc.Disclosure: Dr. Striano has received personal compensation for activities with Shire Pharma and Eisai Inc. Dr. McMurray has received personal compensation for activities with Eisai Ltd. as an employee.

http://www.neurology.org/cgi/content/short/86/16_Supplement/P2.056?rss=1

Source: Neurology - April 3, 2016 Category: Neurology Authors: Striano, P., McMurray, R. Tags: Epilepsy/Clinical Neurophysiology: AEDs Source Type: research